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ABSTRACT
The study was aimed at determining the prevalence of pandemic influenza (H1N1) 2009 among patients 
with respiratory tract diseases during July-December 2009 using real-time reverse transcription polymerase 
chain reaction. Haemagglutination inhibition (HI) assay was performed to detect antibody titres against 
pandemic influenza in 255 medical personnel, 307 members of the general population during the second 
week of December 2009 in Khon Kaen province, Thailand, and in 100 stored sera collected from people of 
different age-groups during 2008. The results showed that the pandemic (H1N1) 2009 had occurred dur-
ing July-December 2009. The results of the HI test after the wave of this outbreak showed that 123 (48%) 
of the 255 sera collected from the medical personnel, 109 (36%) of the 307 sera obtained from the general 
population, and only two of the 100 stored sera from 2008 contained antibodies (HI titres ≥40) against 
pandemic influenza. Antibody against the pandemic (H1N1) 2009 was found in at least one-third of the 
population. In conclusion, the prevalence of virus and serological data obtained from the study can be used 
as the serological background level of the Thai population after the July-December pandemic. Finally, the 
serological data might be useful for outbreak-prevention and control strategies and for the management of 
vaccination for the pandemic (H1N1) 2009 in Thailand. 
Key words: H1N1; Influenza; Serodiagnosis; Surveillance; Thailand
INTRODUCTION
The pandemic influenza (H1N1) 2009 has emerged 
from North America since mid-March 2009 and 
rapidly became responsible for the spread of respi-
ratory illness around the world. Since then, it has 
spread to over 208 countries, and the total number 
of laboratory-confirmed cases of the pandemic 
(H1N1) 2009 has exceeded 414,000, with at least 
18,114 deaths worldwide (28 May 2010) (1). Re-
search has revealed that the strain of virus is a triple 
re-assortant among human, avian and swine influ-
enza viruses (2).
Further evidence has also supported that the hae-
magglutinin protein of this pandemic strain was 
derived from swine (3). An H1N1 virus was first 
identified from samples obtained from humans in 
1918 when there was an outbreak of pandemic in-
fluenza A virus (H1N1) which spread rapidly across 
the world and caused millions of deaths worldwide. 
This worldwide outbreak occurred in several waves 
with increasing virulence (4). 
Transmission patterns of influenza are different ac-
cording to weather conditions, such as temperature 
and humidity (5). As an example, in the Northern 
hemisphere, infections mostly occur from Novem-
ber through March whereas infections occur in the 
Southern hemisphere from July to December, and 
infections in the tropics tend to be spread through-
out the year (6-8). In Thailand, like other tropical 
countries, the rate of infection due to influenza 
is normally sporadic throughout the year. It also 
tends to follow a biphasic seasonal pattern with an 
increase in the infection rate from June to August 
and from January to March (9).
The first confirmed cases of pandemic (H1N1) 2009 
in Thailand were declared by the Bureau of Emerg-
ing Infectious diseases, Department of Disease Con-Prachayangprecha S et al. Human pandemic influenza (H1N1) in Thailand
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trol, Ministry of Public Health, on 12 May 2009 
(10). The pandemic spread through overcrowded 
public areas, such as Pattaya and schools in Bang-
kok, and the virus was probably transmitted from 
person to person by droplet transmission (11). The 
frequency of pandemic (H1N1) 2009 infection was 
generally higher among children and young adults 
compared to seasonal influenza (12). Antigenic and 
genetic characterization of the pandemic (H1N1) 
2009 virus has shown differences between pan-
demic (H1N1) 2009 and seasonal H1N1 influenza 
virus. Hence, the vaccine against human seasonal 
influenza virus (H1N1) is unlikely to provide cross-
reactive immune response against the novel pan-
demic (H1N1) 2009 virus (13).
To determine the host’s immune response, various 
laboratory methods can be applied, such as haemag-
glutination inhibition (HI) test, enzyme-linked im-
munosorbent assay (ELISA), and microneutralization 
(MN) test. The HI test is a widely-used technique for 
measuring specific antibody against influenza as it 
presents a relatively simple and inexpensive meth-
od which has been extensively used in epidemio-
logical studies of influenza virus infection.
In this study, we have investigated pandemic H1N1 
influenza by performing real-time reverse tran-
scription polymerase chain reaction (rRT-PCR) for 
the detection of virus in throat or nasopharyngeal 
swab specimens obtained from randomly-selected 
patients with respiratory tract diseases. Using the 
HI test, we have serologically screened medical per-
sonnel and the general population in Chumphae 
district, Khon Kaen province, Thailand, for specific 
antibodies against the pandemic (H1N1) 2009 vi-
rus. Thus, the evaluation of antibody response to 
the pandemic (H1N1) 2009 among the population 
might be useful for the management of vaccine. 
Data will help prioritize certain groups within the 
population and could also assist in the recommen-
dation for vaccine and management of vaccine 
strategies.
MATERIALS AND METHODS
Sources of specimens 
Chumphae in Khon Kaen province was selected as 
the site for epidemiological studies and surveillance 
on the pandemic (H1N1) 2009. Chumphae district, 
with a population of approximately 650,000, was 
selected for representing a suburban area of Thai-
land. The district is located in the northeast of 
Thailand, approximately 449 km from Bangkok 
(Fig. 1) 
Specimens and sera collected from the participants 
were sent to the Center of Excellence in Clinical 
Virology, Faculty of Medicine, Chulalongkorn Uni-
versity, within 48 hours. The sera were kept at -20 °C 
until tested. 
Nasopharyngeal/throat swab specimens
We collected nasopharyngeal or throat swab sam-
ples from 20 patients (15 outpatients and 5 inpa-
tients) with symptoms of acute respiratory tract 
infection, such as fever, sore throat, cough, rhi-
norrhoea, nasal congestion. Samples were collected 
each week during July 2009–December 2009. The 
specimens were collected in 2 mL of viral transport 
medium containing antibiotics (penicillin G (2 x 
106 U/L) and streptomycin 200 mg/L) kept on ice 
and sent to the Center of Excellence in Clinical Vi-
rology within 48 hours for the diagnosis of influen-
za infection. All the samples were screened for the 
pandemic (H1N1) 2009, human seasonal influenza 
A (H1N1 and H3N2), and influenza B virus by rRT-
PCR (14). 
Population for testing of HI antibody 
In total, 562 cross-sectional serum specimens were 
collected from 7 to 15 December 2009 after the 
July-August wave of the pandemic (H1N1) 2009. 
People diagnosed with immunodeficiency, bleed-
ing disorder, and any chronic respiratory diseases, 
such as bronchial asthma, bronchiectasis, or not 
willing to participate in the study, were excluded. 
The population to be studied was divided into the 
following two groups: 
General population 
Three hundred and seven cross-sectional serum 
Fig. 1. Map  of  Thailand  showing  location  of 
Chumphae district   
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specimens were collected from healthy volun-
teers, devoid of respiratory symptoms, residing 
in Chumphae district by invitation for screening 
of antibody against the pandemic (H1N1) 2009. 
They comprised 185 males and 122 females, with 
a median age of 30 (range 5-92) years. These serum 
samples were included in the study protocol to rep-
resent the baseline for HI seropositivity in the gen-
eral population and then used for comparison with 
healthcare personnel.                  
Healthcare personnel 
Two hundred and fifty-five sera were collected by 
notification from healthcare workers at the Chum-
phae Hospital, Khon Kaen province, for screening 
the pandemic (H1N1) 2009. Their median age was 
32 (range 19-56) years. Sera were divided into three 
groups based on their areas of work.
High-risk group: Specimens were collected from 
healthcare personnel who had close contact with 
patients with respiratory tract disease or collected 
specimens from patients with clinical respiratory 
tract infection during the outbreak of the pandemic 
influenza (H1N1) 2009 or had contact with a per-
son with laboratory-confirmed pandemic (H1N1) 
2009.
Intermediate risk group: Specimens were collected 
from healthcare personnel who worked in a 
high-risk area but were not directly exposed to 
patients with respiratory tract disease or collected 
specimens from patients with clinical respiratory 
tract infection
Low-risk group: Specimens were collected from 
healthcare personnel who work in the hospital but 
were directly exposed to patients, such as office 
workers, electricians, secretaries, and accountants.
Control baseline group
One hundred serum specimens were collected 
from individuals aged 11-86 years from Chum 
Saeng district of Nakhon Sawan province (Fig. 1) 
in March 2008 before the pandemic (H1N1) 2009. 
Stored serum samples were selected from anony-
mous specimens with only the age range known. 
These specimens were collected for a study project 
on antibody to avian influenza (H5N1).
Laboratory methods
Detection of influenza viruses by real-time RT-PCR 
RNA was extracted from 200 μL of each nasopha-
ryngeal swab using the Viral Nucleic Acid Extrac-
tion kit (RBC Bioscience Co, Taiwan) according to 
the protocol of the manufacturer. The extracted 
RNA was used as a template for the detection of in-
fection due to influenza virus. Primers, specific Taq-
Man probes, and thermal profiles for the detection 
were as previously described (12,14,15). rRT-PCR 
was performed using the SuperScript III Platinum 
One-Step  RT-PCR  system  (Invitrogen,  Foster  city, 
CA) in a Rotor-Gene 3000 (Corbett Research, New 
South Wales, Australia).
Propagation of influenza virus 
The pandemic (H1N1) 2009 virus used in the study 
was A/Thailand/CU-H88/09 (accession numbers: 
HM446345 and HM446344). The influenza virus 
was propagated by inoculation of virus stock into 
the allantoic cavity of 10-day old embryonated 
chicken eggs. The inoculated eggs were placed in an 
egg incubator at 37 °C for 48 hours. The allantoic 
fluid was harvested and subjected to centrifugation 
at 3,000 rpm for 10 minutes. The supernatant was 
tested for viral titres by haemagglutination assay 
(HA). Virus-propagation procedures were carried 
out in a biosafety level 2+ (BSL2+) laboratory.
Haemagglutination inhibition assay
To abolish non-specific HIs in serum samples, 
sera were treated with RDE (receptor destroying 
enzyme) produced by Vibrio cholerae Ogawa type 
558 (Denka Seiken, Co. Ltd., Tokyo, Japan) follow-
ing the specifications of the manufacturer. Briefly, 
serum and RDE were mixed in a ratio of 1:3 and 
incubated at 37 °C for 18 hours. Subsequently, the 
mixture was incubated at 56 °C for 30 minutes to 
inactivate the RDE and complement system, fol-
lowed by 10-fold dilution with phosphate-buffered 
saline (PBS). Two-fold serial dilutions of RDE-treat-
ed sera (25 µL) were incubated with eight HA units 
of pandemic influenza virus (25 µL) per well in a 
V-shaped 96-well plate (Greiner Bio-One GmbH, 
Kremsmuenster, Austria) for 30 minutes, followed 
by addition of 50 µL of 0.5% turkey red blood cells 
and incubation at room temperature for 30 min-
utes (16). HI titres of ≥1/40 were considered posi-
tive antibody response.
Statistical analysis
Data were analyzed using the SPSS software for 
windows (version 17). Chi-square test was used for 
comparing the different groups.
Ethics
The Ethics Committee of the Faculty of Medicine, 
Chulalongkorn University, approved the protocol 
of the immunological study. Permission for pan-
demic influenza H1N1 surveillance was granted by 
the director of Chumphae Hospital, Khon Kaen, to Prachayangprecha S et al. Human pandemic influenza (H1N1) in Thailand
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facilitate outbreak control and establish preventive 
measures. All participants were informed about the 
objectives of the study, and their written consents 
were obtained before collection of specimens.
RESULTS
Detection of influenza viruses by real-time 
RT-PCR 
Five hundred and fourteen specimens were col-
lected from children (233 patients) and adults (281 
patients), aged 25 days-86 years. The number of   
samples and percentage positive for the pandemic 
(H1N1) 2009 are depicted in Figure 2. From July, 
the numbers of positive samples increased and 
reached the highest peak by the end of August 
2009 and started to decline from September to 
Fig. 2. Positive percentage of nasopharyngeal or throat swab samples for pandemic (H1N1) 2009 and 
human seasonal inﬂuenza viruses from Chumphae Hospital, Khon Kaen province, Thailand, 
between July and December 2009      
No. of samples Positive %
140
120
100
80
60
40
20
0
Jul Aug Sep Oct NovD ec
50
45
40
38
30
25
20
15
10
5
0
Negative
Positve pandemic
(H1N1) 2009
Positve seasonal
infuenza
% positive
pandemic (H1N1)
2009
% positive ﬂu A
December 2009. In contrast, the seasonal influenza 
strains (H3N2 and influenza B) circulated in a low 
level throughout the year.
HI antibodies against pandemic (H1N1) 2009 
in healthcare personnel 
Based on the HI test performed on 255 healthcare 
personnel at the Chumphae Hospital, 123 samples 
(48%) contained specific antibodies (HI titres ≥40) 
against the pandemic (H1N1) 2009. A comparison 
between groups of medical personnel showed that 
the percentage of samples displaying specific anti-
bodies against the pandemic (H1N1) 2009 was 58% 
(70/120) in the high-risk group, 35% (29/82) in the 
intermediate risk group, and 45% (24/53) in the 
low-risk group. Data are summarized in the table. A 
comparison between antibody-positive risk groups 
showed a significant (p<0.05) difference between 
the high-risk group and the intermediate risk group 
(Table)  
HI antibodies against pandemic (H1N1) 2009 in 
the general population 
The results of the HI test performed on 307 mem-
bers of the general population, aged 5-92 years (age: 
5-10 years: n=18; 11-20 years: n=24; 21-30 years: 
n=11, 31-40 years: n=23; 41-50 years: n=41, 51-60 
years: n=31, 61-70 years: n=30 and over 70 years: 
n=26 ) in Chumphae district showed that 109 sam-
ples (36%) displayed specific antibodies (HI titres 
≥40) against the pandemic (H1N1) 2009. Details 
of the positive HI antibody response (HI titres >40) 
among different age-groups are shown in Figure 3. 
HI antibodies against pandemic (H1N1) 2009 
in 2008 control group 
The results of the HI test showed that two (2%) of 
100 anonymous control sera collected during 2008 
had HI titres of ≥40 against the pandemic (H1N1) 
2009. The positive specimens were derived from 
two individuals aged over 50 years. 
DISCUSSION
In this study, we have performed the HI assay for 
determining the antibody levels against the pan-
demic (H1N1) 2009 to better understand the infec-
tion rate and estimated immunity in the popula-
tion. High numbers of patients diagnosed with 
the pandemic (H1N1) 2009 were observed during Prachayangprecha S et al.
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Fig. 3. Percentage of HI antibody titres against pandemic (H1N1) 2009 in relation to age among 
the general population in Chumphae district, Khon Kaen province, Thailand, 2009
July–September 2009 and then decreased towards 
the end of the year (Fig. 2). The serum samples col-
lected for HI test in December showed high sero-
positivity against the human pandemic (H1N1) 
2009, implying that approximately one-third of 
the Chumphae population developed antibodies 
against the pandemic (H1N1) 2009 at that point 
in time. 
According to a previous study, the HI test in paired 
serum samples of patients with influenza-like ill-
ness (ILI) diagnosed with the pandemic (H1N1) 
2009 showed a significant four-fold increase in an-
tibody titres upon comparison between acute and 
convalescent sera (17). To determine cross-reactivity 
between seasonal influenza and pandemic (H1N1) 
2009, the HI test was performed on acute and 
convalescent sera of patients with ILI and healthy 
young adults collected before the outbreak. The 
results showed that there were no cross-reactivity 
between antibody against the seasonal and pan-
demic (H1N1) 2009.
The HI test performed on sera of the medical per-
sonnel demonstrated a high percentage (48%) of 
samples with a positive HI titre against the pandem-
ic (H1N1) 2009. In all probability, these individuals 
were at a higher risk for infection than the general 
population due to exposure to clinical specimens 
of respiratory tract disease and close contact with 
infected patients. 
A comparison between the individual groups of the 
medical personnel showed that the high-risk group 
exhibited the highest percentage (58%) of antibody 
titres whereas the intermediate risk group and the 
low-risk group presented a lower percentage of an-
tibody titres at 35% and 45% respectively. In the in-
termediate risk group, the positive HI percentages 
were lower than those found in the low-risk group. 
Table. HI antibody titres against pandemic (H1N1) 2009 among healthcare personnel in Chumphae 
Hospital, Khon Kaen province, Thailand, 2009
HI titre
High-risk group
(n=120) 
(47%)
Intermediate risk
group (n=82) 
(33%)
Low-risk group
(n=53) 
(21%)
No. % No. % No. %
20-≤10 50 42 53 65 29 55
40 38 32 15 18 12 23
80 23 19 10 12 9 17
160 8 6 - - 3 5
320 1 1 3 4 - -
640 - - 1 1 - -
Antibody response between high-risk group and intermediate risk group was significant (p<0.05); 
HI titres of ≥40 were used as positive; HI=Haemagglutination inhibitionPrachayangprecha S et al. Human pandemic influenza (H1N1) in Thailand
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The lower HI titres in the intermediate group might 
be due to the level of exposure and personal aware-
ness, including knowledge of appropriate protec-
tion, such as gloves, respiratory mask, and protec-
tive clothing while the low-risk group limited their 
protection to washing their hands. However, the 
antibody response in the intermediate risk group 
did not show a significant difference from that in 
the low-risk group. 
The HI titres among the general population showed 
that 36% of the Chumphae residents already had 
developed immune response against the pandemic 
(H1N1) 2009 virus. Yet, other studies have shown a 
lower rate of seropositivity (11% and 13% in stud-
ies of China and Singapore respectively) (18,19), 
which might have been due to the differences in 
geographic location since various factors, such as 
overcrowding, climate, and personal hygiene, can 
affect the transmission efficiency of virus. Hence, 
the number of people infected with the pandemic 
(H1N1) 2009 may be different in some areas stud-
ied. 
The elevated seroprevalence of the pandemic 
(H1N1) 2009 in the 11-20-year age-group (54%) 
may be explained by schools serving as gathering 
places for children and young adults in class-rooms 
and group activity which create ideal conditions 
for the transmission of the pandemic (H1N1) 2009 
virus, such as lack of or improper handwashing 
and good personal hygiene (20). The 31-40-year 
age-group exhibited 52% seroprevalence. These 
individuals tend to work in air-conditioned offic-
es, use public transport, and attend meetings and 
other social functions, all of which favour trans-
mission of the virus (21). The elderly have possi-
bly acquired partial immunity since around 1977 
when the H1N1 strain with a similar epitope was 
re-introduced into humans (22). In this study, 42% 
of the elderly aged over 70 years displayed antibod-
ies against the pandemic (H1N1) 2009, which may 
have been elicited by previous exposure to a virus 
containing a similar epitope. Thus, the elderly had 
acquired some level of immunity against the pan-
demic influenza A (H1N1) strain. This could ex-
plain the lower rate of infection among the elderly 
people when compared with seasonal influenza 
and, likewise, why the new pandemic strain tended 
to affect the younger age-group (12).
In this study, a comparison of the stored serum 
samples collected in 2008 showed that the HI titre 
was positive in only two specimens derived from 
individuals in the age range of 51-60 years and over 
70 years. A previous study conducted in the United 
States established that one-third of people born 
before 1950 had antibody against the pandemic 
(H1N1) 2009 (22). However, our baseline data from 
2008 revealed a very low prevalence of antibody 
when compared with the results from sera collect-
ed in 2009. This finding was similar to the findings 
from Japan and China obtained from sera collected 
before the outbreak (3,18). 
The results of the HI test showed that the popula-
tion in Chumphae area had developed immunity 
against the pandemic (H1N1) 2009. This level of im-
munity among the population can probably lower 
the infection rate during the next wave due to an 
effect called ‘herd immunity’ (herd immunity=1-1/
R0) (23). Herd immunity can protect non-immu-
nized individuals from infection. The estimated 
basic reproduction number (R0) of the pandemic 
(H1N1) 2009 was 1.4-2.1 (24-26). Once the herd 
immunity reaches 30-50% of the population, it 
will be sufficient to lower and control the infection 
rate of the pandemic (H1N1) 2009. As with previ-
ous patterns of pandemic, the virus can still cause 
sporadic infection in non-immunized individuals, 
although there is no severe outbreak and, at some 
point, the virus will become a common strain that 
continually circulates in the human population.
The HI assay was conducted in this study for de-
termining the antibody levels against human pan-
demic influenza instead of the microneutralization 
assay. This would provide suitable data on neutrali- 
zing antibodies in sera but requires sophisticated 
laboratories for cell culture. The HI test represents 
a simpler screening assay and is a less-expensive 
process, providing acceptable serological data 
which would be feasible and attractive for large-
scale analysis (27).  
Conclusions
Based on the percentage of the pandemic (H1N1) 
2009 cases diagnosed and the antibody levels 
against the pandemic (H1N1) 2009 virus measured, 
this study has shown that the Chumphae popula-
tion had gained some level of immunity to the 
pandemic (H1N1) 2009 during the outbreak be-
tween July and December. Thus, the next pandem-
ic (H1N1) 2009 wave may not impact Thailand as 
severely as suspected, and the disease will become 
seasonal influenza in the near future. This serolog-
ical study has provided useful serological data that 
could help prioritize population groups for vac-
cination against the pandemic (H1N1) 2009 virus. 
Moreover, ongoing serological analysis would be 
essential for the recommendation of vaccine and 
for the development of strategies to prevent future 
epidemics or pandemics.Prachayangprecha S et al.
Volume 28 | Number 6 | December 2010 543
Human pandemic influenza (H1N1) in Thailand
ACKNOWLEDGEMENTS
The authors express their gratitude to the Commis-
sion on Higher Education, Ministry of Education, 
the Center of Excellence in Clinical Virology, Chu-
lalongkorn University, CU Centenary Academic De-
velopment Project, King Chulalongkorn Memorial 
Hospital, Graduate School of Biomedical Science, 
Chulalongkorn University, the RGJ PhD Program 
of the Thailand Research Fund, Ratchadaphisek-
somphot Fund, Chulalongkorn University, and 
MK Restaurant Company Limited for their gener-
ous support. This work was also funded in part with 
federal funds from the NIAID, NIH, Department of 
Health and Human Services, under Contract No. 
HHSN266200700007C. They thank Dr. Praveena 
Kittikhun and Ms Aunyaratana Thontiravong for 
laboratory assistance. They also thank the staff 
and nurses of the Chumphae Hospital, Khon Kaen 
province, Thailand, for their collection of clinical 
data and specimens. Finally, the authors thank Ms 
Petra Hirsch for reviewing the earlier version of the 
manuscript.
REFERENCES 
1.  World Health Organization. Pandemic (H1N1) 2009—
update 102. Geneva: World Health Organization, 
2010. (http://www.who.int/csr/don/2010_05_21/en/
index.html, accessed on 28 May 2010).
2.  Trifonov V, Khiabanian H, Rabadan R. Geographic de-
pendence, surveillance, and origins of the 2009 influ-
enza A (H1N1) virus. N Engl J Med 2009;361:115-9.
3.  ItohY, Shinya K, Kiso M, Watanabe T, SakodaY, Hatta 
M et al. In vitro and in vivo characterization of 
new swine-origin H1N1 influenza viruses. Nature 
2009;460:1021-5.
4.  Miller MA, Viboud C, Balinska M, Simonsen L. The 
signature features of influenza pandemics—implica-
tions for policy. N Engl J Med 2009;360:2595-8.
5.  Lowen AC, Mubareka S, Steel J, Palese P. Influenza vi-
rus transmission is dependent on relative humidity 
and temperature. PLoS Pathog 2007;3:1470-6.
6.  Reichelderfer PS, Kendal AP, Shortridge KF, Hampson 
A. Influenza surveillance in the pacific basin; season-
ality of virus occurrence: a preliminary report. In: 
Chan YC, Doraisingham S, Ling AE, editors. Current 
topics in medical virology. Singapore: World Scien-
tific; 1989:412-44.
7.  Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, Gre-
gory V et al. The global circulation of seasonal influ-
enza A (H3N2) viruses. Science 2008;320:340-6.
8.  Viboud C, Alonso WJ, Simonsen L. Influenza in tro-
pical regions. PloS Med 2006;3:e89.
9.  Simmerman JM, Chittaganpitch M, Levy J, Chantra 
S, Maloney S, Uyeki T et al. Incidence, seasonality 
and mortality associated with influenza pneumonia 
in Thailand: 2005-2008. PLoS One 2009;4:e7776.
10. Thailand. Ministry of Public Health. Department 
of Disease Control. The method of investigation 
and control of influenza A (H1N1) 2009 at the begin-
ning of outbreak at the school and institution. [Thai]. 
(http://203.157.15.4/Flu/doc/Influenza_Investiga-
tion_Manual_June2009.pdf, accessed on 15 June 
2009).
11. Fabian P, McDevitt JJ, DeHaan WH, Fung RO, Cowl-
ing BJ, Chan KH et al. Influenza virus in human 
exhaled breath: an observational study. PLoS One 
2008;3:e2691.
12. Chieochansin T, Makkoch J, Suwannakarn K, Pay-
ungporn S, Poovorawan Y. Novel H1N1 2009 influ-
enza virus infection in Bangkok, Thailand: effects of 
school closures. Asian Biomed 2009;3:469-75.
13. Centers for Disease Control and Prevention. Serum 
cross-reactive antibody response to a novel influen-
za A (H1N1) virus after vaccination with seasonal 
influenza vaccine. MMWR Morb Mortal Wkly Rep  
2009;58:521-4.
14. World Health Organization. CDC protocol of real-
time RTPCR for influenza A (H1N1). Geneva: World 
Health Organization, 2009. 7 p. 
15. Suwannakarn K, Payungporn S, Chieochansin T, 
Samransamruajkit R, Amonsin A, Songserm T et al. 
Typing (A/B) and subtyping (H1/H3/H5) of influenza 
A viruses by multiplex real-time RT-PCR assays. J Virol 
Methods 2008;152:25-31.
16. Kendal AP, Pereira MS, Skehel JJ. Hemagglutination 
inhibition. In: Kendal AP, Pereira MS, Skehel JJ, edi-
tors. Concepts and procedures for laboratory-based 
influenza surveillance. Atlanta, GA: Centers for Dis-
ease Control, 1982:B17-35 p.
17. Makkoch J, Payungporn S, Prachayangprecha S, Tan-
tilertcharoen R, Poovorawan Y. Determination of an-
tibody response to the human pandemic influenza 
H1N1 2009 among patients with influenza-like ill-
ness and high risk groups. Asian Pac J Allergy Immunol 
2010;28:67-75.
18. Chen H, Wang Y, Liu W, Zhang J, Dong B, Fan X et 
al. Serological survey of pandemic (H1N1) 2009 vi-
rus, Guangxi province, China (letter). Emerg Infect Dis 
2009;15:1849-50.
19. Chen MI, Lee VJ, Lim WY, Barr IG, Lin RT, Koh GC et 
al. 2009 influenza A (H1N1) seroconversion rates 
and risk factors among distinct adult cohorts in Sin-
gapore. JAMA 2010;303:1383-91.
20. Cowling BJ, Chan KH, Fang VJ, Cheng CK, Fung RO, 
Wai W et al. Facemasks and hand hygiene to prevent 
influenza transmission in households: a cluster rand-Prachayangprecha S et al. Human pandemic influenza (H1N1) in Thailand
JHPN 544
omized trial. Ann Intern Med 2009;151:437-46.
21. Mossong J, Hens N, Jit M, Beutels P, Auranen K, 
Mikolajczyk R et al. Social contacts and mixing pat-
terns relevant to the spread of infectious diseases. 
PLoS Med 2008;5:e74.
22. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, 
Sun H et al. Cross-reactive antibody responses to the 
2009 pandemic H1N1 influenza virus. N Engl J Med 
2009;361:1945-52.
23. Anderson MR. Analytical theory of epidemics. In: 
Krause RM, editor. Biomedical research reports: 
emerging infections. 2nd ed. California, CA: Aca-
demic Press, 2000:23-50. 
24.  Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van 
Kerkhove MD, Hollingsworth TD et al. Pandemic po- Pandemic po-
tential of a strain of influenza A (H1N1): early find-
ings. Science 2009;324:1557-61. 
25. Nishiura H, Wilson N, Baker MG. Estimating the re- Estimating the re-
production number of the novel influenza A virus 
(H1N1) in a southern Hemisphere setting: preliminary 
estimate in New Zealand. N Z Med J 2009;122:73-7.
26. Nishiura H, Castillo-Chavez C, Safan M, Chowell 
G. Transmission potential of the new influenza A 
(H1N1) virus and its age-specificity in Japan. Eurosur-
veillance 2009;14:1-4.
27. Rowe T, Abernathy RA, Hu-Primmer J, Thompson 
WW, Lu X, Lim W et al. Detection of antibody to 
avian influenza A (H5N1) virus in human serum by 
using a combination of serologic assays. J Clin Micro-
biol 1999;37:937-43.